Chetan Lathia

General Counsel at BIOXCEL THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

Chetan D.
Lathia is currently the Senior Vice President & Head-Regulatory Affairs at BioXcel Therapeutics, Inc. He previously worked as the Executive Director-Clinical Pharmacology at Alexion Pharmaceuticals, Inc. and as the VP & Head-Clinical Pharmacology at Intarcia Therapeutics, Inc. Lathia holds a doctorate degree from Virginia Commonwealth University and an undergraduate degree from L.
M.
College of Pharmacy.

Chetan Lathia active positions

Companies	Position	Start
BIOXCEL THERAPEUTICS, INC.	General Counsel	-

All active positions of Chetan Lathia

Former positions of Chetan Lathia

Companies	Position	End
ALEXION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Corporate Officer/Principal	-

See the detail of Chetan Lathia's experience

Training of Chetan Lathia

Virginia Commonwealth University	Doctorate Degree
L. M. College of Pharmacy	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Chetan Lathia's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BIOXCEL THERAPEUTICS, INC.	Health Technology

Private companies	2
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.	Health Technology